Singaporean medtech Us2.ai gets CE mark for automated cardiac ultrasound software
Mobi Health News - ECG
JUNE 8, 2022
The company is also close to getting its patent for the Us2.v1 software recognised in the US.
Mobi Health News - ECG
JUNE 8, 2022
The company is also close to getting its patent for the Us2.v1 software recognised in the US.
Open Heart
JUNE 9, 2022
Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heart failure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality. Methods and results Randomised controlled trials (RCTs) published through 20 June 2021 were identified from six databases, and reference lists of inc
The Beat Blog
JUNE 9, 2022
Are there ways to simplify specialty care, like heart care, for PACE plans? Scheduling an in-person visit with a cardiologist is downright difficult. Nationally, it takes upwards of 45 days to see one and the prospect of getting yourself there can be a challenge for many. For PACE plans (Program of All Inclusive Care for the Elderly) who manage care for thousands of individuals in their network – this reality is an incredible challenge and extends beyond one speciality area like heart care.
ECG Cases
JUNE 7, 2022
In this part 2 of our 2-part podcast series on Cardiac Arrest - The When, Why & How, we discuss some of the finer art of cardiac arrest care and answer questions such as: how should we best communicate to EMS, the ED team and the family of the patient to keep the team focused, garner the most important info and keep the flow of the code going? How should we integrate PoCUS into cardiac arrest care so we do not interrupt the core components, yet we gain valuable data?
iRythm Technologies
JUNE 8, 2022
CEO of iRhythm Technologies Quentin Blackford discusses his vision for the company and shares his thoughts on the future of wearables in the healthcare industry.
Open Heart
JUNE 8, 2022
Objective Pulmonary arterial hypertension (PAH), caused by pulmonary artery remodelling and increased pulmonary vascular resistance (PVR) due to an unknown mechanism, is an intractable disease with a poor prognosis. The recent development of PAH-specific treatment medications may allow for higher PVR reduction than previously achieved. This study aimed to identify the prognostic significance of follow-up PVR levels achieved shortly after the initiation of targeted treatment in patients with idio
Open Heart
JUNE 9, 2022
Objective Pregnancy is associated with elevated risk of cardiovascular diseases (CVD), but little is known regarding the association between CVD and specific types of pregnancy losses. The aim of this study is to investigate the effects of pregnancy loss on the risk of subsequent CVD of any type. Methods This prospective longitudinal study examines medical records between 1999 and 2014 for Medicaid beneficiaries born after 1982 who lived in a state that funds all reproductive health services, in
Let's personalize your content